Join to access to all OVN content. Join for Free

Results for 'digital tools'

...
Partner Avatar Tom Caravela
MSL People Skills: Top 10 Tips for Better Engagement

Apr 20th • 8 mins read

...
Partner Avatar iNIZIO
Transforming oncology: Five frontiers driving progress in cancer care

May 16th • 5 mins read

...
OVN Avatar Shani Paluch-Shimon, Nathan I. Cherny, Elisabeth G.E. de Vries, Urania Dafni, Martine J. Piccart, Nicola Jane Latino, Fatima Cardoso
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies

Sep 6th • 20 mins read

...
OVN Avatar Nicole Grossmann, Martin Robausch, Eleen Rothschedl, Claudia Wild, Judit Simon
Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015

Feb 23rd • 12 mins read

...
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer
Value assessment of oncology drugs using a weighted criterion-based approach

Dec 20th • 15 mins read

...
OVN Avatar Guillaume Beinse, MD, Virgile Tellier, Valentin Charvet, MSc, Eric Deutsch, MD, PhD, Isabelle Borget, PharmD, PhD, Christophe Massard, MD, PhD., Antoine Hollebecque, MD, PhD, and Loic Verlingue, MD
Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2

Sep 20th • 12 mins read

...
OVN Avatar Consolacion Molto, Ariadna Tibau, Aida Bujosa, Jose Carlos Tapia, Abhenil Mittal, Faris Tamimi & Eitan Amir
Association between control group therapy and magnitude of clinical benefit of cancer drugs

Dec 9th • 20 mins read

...
Partner Avatar Envision Pharma Group
Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?

May 9th • 5 mins read

...
Partner Avatar Envision Pharma Group
Medical affairs: The power behind redefining commercialization

Aug 2nd • 3 mins read

...
Partner Avatar Envision Pharma Group
Empowering people to drive medical affairs performance with AI

Aug 14th • 5 mins read

...
OVN Avatar Laurent Azoulay
Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective

Apr 26th • 9 mins read

...
OVN Avatar Francesco Cerisoli, PhD, Farzad Ali, MSc, Tamás Bereczky, MA, PhD, Natacha Bolaños, BS, Lars Bullinger, MD, Sujith Dhanasiri, MPhil, MSc, James Gallagher, PhD, Sonia García Pérez, MSc, Jan Geissler, MiBA, Yann Guillevic, DEA, Kathryn Harrison, PhD, Anasta
Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools

May 17th • 12 mins read

...
OVN Avatar M. Bertagnolli and J. Tabernero
Value assessment frameworks in oncology: championing concordance through shared standards

Feb 18th • 1 min read

...
Partner Avatar Envision Pharma Group
AI-powered real-world evidence: Strategically enhancing value and access

Aug 22nd • 5 mins read